<DOC>
	<DOCNO>NCT02897219</DOCNO>
	<brief_summary>The objective study confirm efficacy ASP1941 base change HbA1c ass safety subject type 1 diabetes mellitus receive ASP1941 daily combination insulin 24 week . This study also assess safety/efficacy long-term treatment ( 52 week ) .</brief_summary>
	<brief_title>A Study ASP1941 Combination With Insulin Patients With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>This study consist two part . In Part 1 , ASP1941 placebo administer orally blind manner . In Part 2 , long-term safety efficacy ASP1941 evaluate patient participate study complete Part 1 .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>The subject diagnose type 1 diabetes mellitus The subject receive insulin therapy treatment diabetes mellitus . The subject switch insulin product another insulin product switch continuous subcutaneous insulin infusion ( CSII ) multiple daily injection ( MDI ) . The subject HbA1c value 7.5 % 11.0 % difference HbA1c value within ± 2.0 % . The subject fasting blood Cpeptide level &lt; 0.6 ng/mL . The subject body mass index ( BMI ) 20.0 kg/m2 35.0 kg/m2 . The subject type 2 diabetes mellitus . The subject participate clinical study post marketing study another drug medical equipment within 12 week ( 84 day ) provide write informed consent , currently participate study . The subject receive treatment ASP1941 ( ipragliflozin ) participate clinical study ASP1941 ( exclude subject discontinue investigational period ) . The subject participate study previously . The subject receive hypoglycemic agent insulin αglucosidase inhibitor . The subject proliferative retinopathy ( except undergone photocoagulation etc . whose symptom stable ) . The subject experience severe hypoglycemia . The subject experience diabetic ketoacidosis . The subject chronic disease require continuous use corticosteroid , immunosuppressant , etc . The subject symptomatic urinary tract infection symptomatic genital infection . The subject history recurrent urinary tract infection recurrent genital infection . The subject history cerebral vascular attack , unstable angina , myocardial infarction , vascular intervention , another serious heart disease . The subject concomitant malignant tumor history malignant tumor The subject history allergy ASP1941 ( ipragliflozin ) and/or similar drug ( drug possess SGLT2 inhibitory action ) . The subject psychiatric disorder inappropriate participation study . The subject drug addiction alcohol abuse . The subject severe infection serious trauma , perioperative . The subject history medically significant renal disease renovascular occlusive disease , nephrectomy and/or renal transplant . The subject symptom dysuria , anuria , oliguria , urinary retention . The subject severe renal impairment endstage renal failure require dialysis . The subject Aspartate Aminotransferase and/or Alanine Aminotransferase value exceed 2 time , total bilirubin value exceed 1.5 time upper limit reference range . The subject uncontrolled severe hypertension . The subject serious gastrointestinal disease history operation serious gastrointestinal disease .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>SGLT2 inhibitor</keyword>
	<keyword>ASP1941</keyword>
	<keyword>type 1 diabetes mellitus</keyword>
</DOC>